IV Ciprofloxacin-Induced Phlebitis: Investigating the Impact of Pharmaceutical and Process-Related Factors on Patient Safety

Sareh  Hosseini; Alireza  Mohammadi; Alborz  Fattahi; Shiva  Hashemi; Yasaman  Khajeamiri; Saeed  Maleki

doi:10.18502/jpc.v12i3.16775

Sareh Hosseini Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch (IAUPS), Tehran, Iran.
Alireza Mohammadi Ronak Pharmaceutical Co., Tehran, Iran.
Alborz Fattahi Ronak Pharmaceutical Co., Tehran, Iran.
Shiva Hashemi Ronak Pharmaceutical Co., Tehran, Iran.
Yasaman Khajeamiri Department of Pharmacovigilance, Ronak Pharmaceutical Co., Tehran, Iran.
Saeed Maleki Ronak Pharmaceutical Co., Tehran, Iran.

DOI: https://doi.org/10.18502/jpc.v12i3.16775

Keywords: Thrombophlebitis; Pharmacovigilance; Adverse drug reaction

Abstract

Transient phlebitis is a rare but notable adverse reaction that can occur following intravenous administration of various medications, including ciprofloxacin, an antibiotic recognized for its broad-spectrum activity. This case report discusses a 48-year-old male patient with poorly controlled type 2 diabetes who developed phlebitis after receiving undiluted ciprofloxacin via a peripheral intravenous line. Symptoms emerged within 24 hours, characterized by swelling and redness at the injection site, prompting the discontinuation of the medication. Analysis revealed that improper dilution and rapid infusion rate were major factors contributing to the development of phlebitis. This underscores the importance of adhering to guidelines provided in product information leaflets for intravenous drug preparation and administration. The case emphasizes the critical need for healthcare professionals to follow recommended protocols to reduce the risk of infusion-related complications, especially in patients with underlying comorbidities.